Dialing down the toxic effects of radiotherapy on cancer patients, Galera gets breakthrough status on Phase IIb data

A biotechnology company near Philadelphia — armed with data from a Phase IIb trial — just got breakthrough status from the FDA for a drug that might reduce the harmful effects of radiotherapy for cancer patients.
End Points